Finance Q&A
(2009-04-23)
Listen Now:
SEATTLE, WA
(KPLU) -
A Seattle biotech company, Dendreon, is developing a treatment for late-stage prostate cancer. It's hoping to produce the first cancer vaccine to receive FDA approval. KPLU's Dave Meyer looks at the company with financial commentator Greg Heberlein.
© Copyright 2012, KPLU
null
